How to read your patient’s test results
The Oncodetect® molecular residual disease (MRD) test report is simple and straightforward, showing whether circulating tumor DNA (ctDNA) was detected in your patient’s blood, as well as a chart of their ctDNA levels over time.

Explore the report
Positive or negative
The report begins with a positive or negative result (detected or not detected), indicating the presence or absence of ctDNA associated with your patient’s tumor. A positive result correlates with a higher risk of cancer recurrence or progression. A negative result correlates with a better prognosis for the patient.

Amount detected
If ctDNA is detected,
Longitudinal monitoring
Track your patient’s ctDNA levels over time — pre-surgery, post-surgery, during and after adjuvant therapy, during patient surveillance, and, as needed, upon recurrence. This lets you monitor tumor burden, detect recurrence, and assess response to therapy.
Breaking down the results
Each Oncodetect MRD report will show the amount of tumor-specific ctDNA in your patient’s bloodstream. If you are monitoring MRD over time, you’ll get a historical view of your patient’s levels, showing quantifiable evidence suggesting cancer recurrence, progression, or regression.
Negative
A “ctDNA not detected” result indicates there is no identifiable evidence of MRD, and could signify a lower risk of recurrence or progression.

Positive
A “ctDNA detected” result is correlated with a higher risk of recurrence or progression. Knowledge of a positive result and the trajectory of ctDNA levels over time can help inform the best treatment plan for a patient.

View your patient’s Oncodetect test results on the Exact Sciences Provider Hub.
We’re here to support you. If you need any help interpreting results,
